Advertisement

International Journal of Hematology

, Volume 73, Issue 2, pp 177–187 | Cite as

Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical Application

  • Haruo Sugiyama
Review Article

Abstract

The Wilms’ tumor geneWT1 is a gene responsible for the childhood renal tumor, Wilms’ tumor, and is defined as a tumor suppressor gene. However, the wild-typeWT1 gene is highly expressed in leukemic blast cells of myeloid and lymphoid origin, and thus,WT1 messenger RNA provides a novel tumor marker for detection of minimal residual disease of leukemias and for monitoring disease progression of myelodysplastic syndromes. TheWT1 gene exerts an oncogenic function rather than a tumor-suppressor gene function in solid tumors as well as leukemias, and the WT1 gene product is an attractive tumor antigen capable of eliciting cytotoxic T lymphocytes againstWT1-expressing tumors.

Key words

Wilms’ tumor geneWT1 Minimal residual disease Myelodysplastic syndromes Immunotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus.Cell. 1990;60:509–520.CrossRefPubMedGoogle Scholar
  2. 2.
    Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.Nature. 1990;343:774–778.CrossRefPubMedGoogle Scholar
  3. 3.
    Coppes MJ, Campbell CE, Williams BR. The role of WT1 in Wilms tumorigenesis [review].FASEB J. 1993;7:886–895.CrossRefPubMedGoogle Scholar
  4. 4.
    Rauscher FJ III. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor [review].FASEB J. 1993;7:896–903.CrossRefPubMedGoogle Scholar
  5. 5.
    Haber DA, Park S, Maheswaran S, et al. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.Science. 1993;262:2057–2059.CrossRefPubMedGoogle Scholar
  6. 6.
    Algar EM, Kenney MT, Simms LA, Smith SI, Kida Y, Smith PJ. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms’ tumour associated with high levels of expression of a truncated transcript.Hum Mutat. 1995;5:221–227.CrossRefPubMedGoogle Scholar
  7. 7.
    Little M, Wells C. A clinical overview of WT1 gene mutations [review].Hum Mutat. 1997;9:209–225.CrossRefPubMedGoogle Scholar
  8. 8.
    Gashler AL, Bonthron DT, Madden SL, Rauscher FJ III, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.Proc Natl Acad Sci U S A. 1992;89:10984–10988.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ III. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms’ tumor locus.J Biol Chem. 1993;268:21271–21275.PubMedGoogle Scholar
  10. 10.
    Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ III. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.Science. 1992;257:674–678.CrossRefPubMedGoogle Scholar
  11. 11.
    Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product.Proc Natl Acad Sci U S A. 1993;9:5828–5832.CrossRefGoogle Scholar
  12. 12.
    Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.EMBO J. 1995;14:4662–4675.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-α gene by the Wilms tumor suppressor gene product, wt1.Oncogene. 1995;10:1125–1129.PubMedGoogle Scholar
  14. 14.
    McCann S, Sullivan J, Guerra J, Arcinas M, Boxer LM. Repression of the c-myb gene by WT1 protein in T and B cell lines.J Biol Chem. 1995;270:23785–23789.CrossRefPubMedGoogle Scholar
  15. 15.
    Hewitt SM, Hamada S, McDonnel TJ, Rauscher FJ III, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms’ tumor suppressor gene WT1.Cancer Res. 1995;55;5386–5389.PubMedGoogle Scholar
  16. 16.
    Li RS, Law GL, Seifert RA, Romaniuk PJ, Morris DR. Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1.Exp Cell Res. 1999;247:257–266.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang X, Xing G, Saunders GF. Proto-oncogene N-myc promoter is down regulated by the Wilms’ tumor suppressor gene WT1.Anti-cancer Res. 1999;19:1641–1648.Google Scholar
  18. 18.
    Guan LS, Rauchman M, Wang ZY. Induction of Rb-associated protein (RbAp46) by Wilms’ tumor suppressor WT1 mediates growth inhibition.J Biol Chem. 1998;273:27047–27050.CrossRefPubMedGoogle Scholar
  19. 19.
    Kim J, Prawitt D, Bardeesy N, et al. The Wilms’ tumor suppressor gene (WT1) product regulates Dax-1 gene expression during gonadal differentiation.Mol Cell Biol. 1999;19:2289–2299.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene.EMBO J. 1999;18:3990–4003.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms’ tumor gene (WT1) during kidney development.Mol Cell Biol. 1991;11: 1707–1712.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Park S, Schalling M, Bernard A, et al. The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma.Nat Genet. 1993;4:415–420.CrossRefPubMedGoogle Scholar
  23. 23.
    Davies R, Moore A, Schedl A, et al. Multiple roles for the Wilms’ tumor suppressor, WT1 [review].Cancer Res. 1999;59(suppl 7):1747s-1750s; discussion 1751s.PubMedGoogle Scholar
  24. 24.
    Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.Development. 1999;126:1845–1857.PubMedGoogle Scholar
  25. 25.
    Miwa H, Beran M, Saunders GF. Expression of the Wilms tumor gene (WT1) in human leukemias.Leukemia. 1992;6:405–409.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilms’ tumor gene, WT1, in human leukemia cells.Leukemia. 1993;7:970–977.PubMedGoogle Scholar
  27. 27.
    Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.Blood. 1994;84:3071–3079.PubMedGoogle Scholar
  28. 28.
    Bergmann L, Miething C, Maurer U, et al. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.Blood. 1997;90:1217–1225.PubMedGoogle Scholar
  29. 29.
    Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms’ tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells.Leukemia. 1994;8:2138–2143.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.Leukemia. 1995;9:1060–1067.PubMedGoogle Scholar
  31. 31.
    Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E. Detection by monoclonal antibodies of the Wilms’ tumor (WT1) nuclear protein in patients with acute leukemia.Int J Cancer. 1997;70:518–523.CrossRefPubMedGoogle Scholar
  32. 32.
    Patmasiriwat P, Fraizer GC, Claxton D, Kantarjian H, Saunders GF. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities.Leukemia. 1996;10:1127–1133.PubMedGoogle Scholar
  33. 33.
    Im HJ, Kong G, Lee H. Expression of Wilms tumor gene (WT1) in children with acute leukemia.Pediatr Hematol Oncol. 1999;16: 109–118.CrossRefPubMedGoogle Scholar
  34. 34.
    Tamaki H, Ogawa H, Inoue K, et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia.Blood. 1996;88:4396–4399.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.Blood. 1996;88:2267–2278.PubMedGoogle Scholar
  36. 36.
    Bergmann L, Maurer U, Weidmann E. Wilms tumor gene expression in acute myeloid leukemias.Leuk Lymphoma. 1997;25:435–443.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ogawa H, Tsuboi A, Oji Y, et al. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay.Bone Marrow Transplant. 1998;21:525–527.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Sugiyama H. Wilms’ tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia [review].Leuk Lymphoma. 1998;30:55–61.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.Leukemia. 1999;13:393–399.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Sako M, Ogawa H, Okamura J, et al. Abnormal expression of the Wilms’ tumor gene WT1 in juvenile chronic myeloid leukemia and infantile monosomy 7 syndrome.Leuk Res. 1998;22:965–967.CrossRefPubMedGoogle Scholar
  41. 41.
    Menssen HD, Renkl HJ, Reider H, et al. Distinction of eosinophilic leukaemia from idiopathic hypereosinophilic syndrome by analysis of Wilms’ tumor gene expression.Brit J Haematol. 1998;101:325–334.CrossRefGoogle Scholar
  42. 42.
    Bruening W, Gros P, Sato T, et al. Analysis of the 11p13 Wilms’ tumor suppressor gene (WT1) in ovarian tumors.Cancer Invest. 1993;11:393–399.CrossRefPubMedGoogle Scholar
  43. 43.
    Viel A, Giannini F, Capozzi E, et al. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors.Int J Cancer. 1994;57:515–521.CrossRefPubMedGoogle Scholar
  44. 44.
    Campbell CE, Kuriyan NP, Rackley RR, et al. Constitutive expression of the Wilms’ tumor suppressor gene (WT1) in renal cell carcinoma.Int J Cancer. 1998;78:182–188.CrossRefPubMedGoogle Scholar
  45. 45.
    Walker C, Rutten F, Yuan X, Pass H, Mew DM, Everitt J. Wilms’ tumor suppressor gene expression in rat and human mesothelioma.Cancer Res. 1994;54:3101–3106.PubMedGoogle Scholar
  46. 46.
    Amin KM, Litzky LA, Smythe WR, et al. Wilms’ tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.Am J Pathol. 1995;146:344–356.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Langerak AW, Williamson KA, Miyagawa K, Hagemeijer A, Versnel MA, Hastie ND. Expression of the Wilms’ tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression.Genes Chromosomes Cancer. 1995;12:87–96.CrossRefPubMedGoogle Scholar
  48. 48.
    Rodeck U, Bossler A, Kari C, et al. Expression of the wt1 Wilms’ tumor gene by normal and malignant human melanocytes.Int J Cancer. 1994;59:78–82.CrossRefPubMedGoogle Scholar
  49. 49.
    Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor.Cancer Res. 1994;54:2837–2840.PubMedGoogle Scholar
  50. 50.
    Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr, Daniel CW. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer.Proc Natl Acad Sci U S A. 1997;94:8132–8137.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth.Jpn J Cancer Res. 1999;90:194–204.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Menssen HD, Bertelmann E, Bartelt S, et al. Wilms’ tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens.J Cancer Res Clin Oncol. 2000;126:226–232.CrossRefPubMedGoogle Scholar
  53. 53.
    Harada Y, Nonomura N, Nishimura K, et al. The WT1 expression in human testicular germ cell tumors.Mol Urol. 1999;3: 357–363.PubMedGoogle Scholar
  54. 54.
    Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.Blood. 1997;89:1405–1412.PubMedGoogle Scholar
  55. 55.
    Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis.Blood. 1996;87:2878–2884.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Inoue K, Tamaki H, Ogawa H, et al. Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells.Blood. 1998;91:2969–2976.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Tsuboi A, Oka Y, Ogawa H, et al. Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF).Leuk Res. 1999;23: 499–505.CrossRefPubMedGoogle Scholar
  58. 58.
    Osaka M, Koami K, Sugiyama T. WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracence (DMBA)-induced leukemia.Int J Cancer. 1997;72:696–699.CrossRefPubMedGoogle Scholar
  59. 59.
    Maheswaran S, Park S, Bernard A, et al. Physical and functional interaction between WT1 and p53 proteins.Proc Natl Acad Sci U S A. 1993;90:5100–5104.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Johnstone RW, See RH, Sells SF, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms’ tumor suppressor WT1.Mol Cell Biol. 1996;16:6945–6956.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Johnstone RW, Wang J, Tommerup N, Vissing H, Roberts T, Shi Y. Ciao 1 is a novel WD40 protein that interacts with the tumor suppressor protein WT1.J Biol Chem. 1998;273:10880–10887.CrossRefPubMedGoogle Scholar
  62. 62.
    Algar E, Blackburn D, Kromykh T, Taylor G, Smith P. Mutation analysis of the WT1 gene in sporadic childhood leukaemia.Leukemia. 1997;11:110–113.CrossRefPubMedGoogle Scholar
  63. 63.
    Carapeti M, Goldman JM, Cross NC. Dominant-negative mutations of the Wilms’ tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia.Eur J Haematol. 1997;58:346–349.CrossRefPubMedGoogle Scholar
  64. 64.
    King-Underwood L, Renshow J, Pritchard-Jones K. Mutations in the Wilms’ tumor gene WT1 in leukemias.Blood. 1996;87:2171–2179.PubMedGoogle Scholar
  65. 65.
    King-Underwood L, Pritchard-Jones K. Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.Blood. 1998;91:2961–2968.PubMedGoogle Scholar
  66. 66.
    Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya K. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.Genes Chromosomes Cancer. 1999;25:176–183.CrossRefPubMedGoogle Scholar
  67. 67.
    Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product.J Immunol. 2000;164:1873–1880.CrossRefPubMedGoogle Scholar
  68. 68.
    Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination.J Clin Immunol. 2000;20:195–202.CrossRefPubMedGoogle Scholar
  69. 69.
    Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of wild-type Wilms’ tumor gene WT1 product.Immunogenetics. 2000;51:99–107.CrossRefPubMedGoogle Scholar
  70. 70.
    Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.Blood. 2000;95:2198–2203.PubMedGoogle Scholar
  71. 71.
    Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.Blood. 2000;95:286–293.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  1. 1.Department of Clinical Laboratory ScienceOsaka University Medical SchoolOsakaJapan

Personalised recommendations